Can I read Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials on EtoBox?

Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials by Chen, Mei-Jyh (author);Chen, Po-Yueh (author);Fang, Yu-Jen (author);Bair, Ming-Jong (author);Chen, Chieh-Chang (author);Chen, Chien-Chuan (author);Yang, Tsung-Hua (author);Lee, Ji-Yuh (author);Yu, Chien-Chun (author);Kuo, Chia-Chi (author);Chiu, Min-Chin (author);Chou, Chu-Kuang (author);Chen, Chi-Yi (author);Hu, Wen-Hao (author);Tsai, Min-Horn (author);Hsu, Yao-Chun (author);Shun, Chia-Tung (author);Luo, Jiing-Chyuan (author);Lin, Jaw-Town (author);El-Omar, Emad M (author);Wu, Ming-Shiang (author);Liou, Jyh-Ming (author) is a Medicine article available to read on EtoBox.

What is Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials about?

Background Helicobacter pylori infection is an important causal factor of gastric cancer and peptic ulcer disease and is associated with immune thrombocytopenic purpura and functional dyspepsia. In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin resistance, respectively. Whether the efficacy of molecular testing-guided therapy is non-inferior to that of susceptibility testing-guided therapy for H pylori eradication is unclear. Therefore, we aimed to compare the efficacy and safety of molecular testing-guided therapy and traditional culture-based susceptibility testing-guided therapy in first-line and third-line treatment of H pylori infection. Methods We did two multicentre, open-label randomised trials in Taiwan. In trial 1 (done at seven hospitals), treatmentnaive individuals infected with H pylori who were aged 20 years or older were eligible for study inclusion. In trial 2 (done at six hospitals), individuals aged 20 years or older who failed treatment after two or more eradication therapies for H pylori infection were eligible for enrolment. Eligible patients were randomly assigned (1:1) to receive

Who reads Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials?

Author

Chen, Mei-Jyh (author);Chen, Po-Yueh (author);Fang, Yu-Jen (author);Bair, Ming-Jong (author);Chen, Chieh-Chang (author);Chen, Chien-Chuan (author);Yang, Tsung-Hua (author);Lee, Ji-Yuh (author);Yu, Chien-Chun (author);Kuo, Chia-Chi (author);Chiu, Min-Chin (author);Chou, Chu-Kuang (author);Chen, Chi-Yi (author);Hu, Wen-Hao (author);Tsai, Min-Horn (author);Hsu, Yao-Chun (author);Shun, Chia-Tung (author);Luo, Jiing-Chyuan (author);Lin, Jaw-Town (author);El-Omar, Emad M (author);Wu, Ming-Shiang (author);Liou, Jyh-Ming (author)

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)